Revenue Recognition - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended		90 Months Ended
	May 05, 2020	Jan. 31, 2015	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Prior period performance obligation revenue recognized					$ 21,200	$ 28,500
Overpayment reimbursement liability			$ 1,500		1,500		$ 1,500	$ 5,000
Revenue recognized					17
Total revenues			309,893	$ 442,408	639,111	987,573
Rayaldee
Disaggregation of Revenue [Line Items]
Revenue recognized			6,200	5,000	11,300	10,800
Total revenues			15,382	16,122	28,861	31,767
Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues			87,197	9,548	93,159	13,816
Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 3,000
Pfizer | Products
Disaggregation of Revenue [Line Items]
Revenue recognized							$ 85,000
Maximum milestone payments		$ 275,000
Initial upfront payment		$ 295,000
Pfizer | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues			$ 2,300	$ 2,800	4,500	$ 5,600
Maximum milestone payments					85,000
VFMCRP | Products | Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues					3,000
Nicoya
Disaggregation of Revenue [Line Items]
Initial upfront payment					$ 5,000